// App-Quantinova.ai

2439 : Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150 increases the chemosensitivity and decreases tumor-initiating potential of neuroblastoma cells

Researchers

Presenter

  • Seiichi Odate

Principal Investigators

  • Shuang Yan

  • Veronica Veschi

  • Norris Lam

  • Zhihui Liu

  • Carol J. Thiele

Medical Centers

  • National Cancer Institute, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Neuroblastoma

  • Solid malignancies

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • cMYC

  • Janus kinase

Drug/Treatment

  • Tetracycline

  • Cisplatin

  • AZD-9150

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved